| Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
The Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) is a multicenter, randomized, single blind, two-arm, placebo controlled Phase III trial with blinded outcome assessments to establish the safety and efficacy of single dose of convalescent plasma for preventing the progression from mild to severe COVID-19 illness.
- Study Design:
- Clinical Trial
- Study Type:
- Clinical Trial
- Total number of consented subjects: 511
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
-
- BioProject
- PubMed
- PMC
- Clinical Trials
- Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: COVID-19
- Authorized Data Access Requests
-
See articles in PMC citing this study accession
- Study Attribution
-
-
Principal Investigator
- Clifton Callaway. University of Pittsburgh, Pittsburgh, PA, USA.
-
Principal Investigator